Estradiol Patch
Product Images NDC 50090-7987

Product Visual Gallery

This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Estradiol (NDC 50090-7987). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Estradiol Structural Formula (Image 01)

Chemical structure of estradiol including a half molecule of water (hemihydrate). The diagram shows the steroid backbone with multiple rings and hydroxyl groups.*

FDA Label Image

Transdermal Parts (Image 02)

An illustration diagram showing the layered structure of an Estradiol transdermal patch. It depicts four layers: foam backing with adhesive layer, polyester film, acrylate adhesive matrix containing estradiol, and a protective liner.*

FDA Label Image

Figure 1 Mean Serum 17β-estradiol Concentrations Vs. Time Profile Following Application Of A 7.75 Cm2 Transdermal Patch And Application Of A 15.5 Cm2 Estradiol Transdermal System Continuous Delivery (once-weekly) Patch (Image 03)

Chart showing concentrations (pg/mL) of estradiol over time (hours) for two transdermal systems with different surface areas (7.75 cm² and 4.625 cm²). Concentration curves peak early and decline gradually over 180 hours, comparing estradiol levels delivered by each system.*

FDA Label Image

Figure 2 Observed Mean (± S.e.) Estradiol Serum Concentrations For A One Week Application Of The Estradiol Transdermal System Continuous Delivery (once-weekly) (31 Cm2) To The Abdomen And Buttocks Of 38 Postmenopausal Women (Image 04)

A line graph comparing mean concentration levels (pg/mL) over time (hours after patch application) for two treatment sites: buttock and abdomen. The x-axis represents sampling time from 0 to 192 hours, while the y-axis shows mean concentration values. Data points include error bars indicating variability.*

FDA Label Image

Figure 3 Mean Percent Change From Baseline In Lumbar Spine (a-p View) Bone Mineral Density By Treatment And Time Last Observation Carried Forward (Image 05)

A line graph displaying percent change over time from baseline to 24 months. The x-axis shows visits at baseline, 6, 12, 18, and 24 months. The graph compares treatment groups of placebo and three patch sizes (7.75 cm², 15.5 cm², and 18.6 cm², plus 31 cm²) with different lines and symbols representing each group.*

FDA Label Image

Figure 4 Mean Percent Change From Baseline In Total Hip By Treatment And Time Last Observation Carried Forward (Image 06)

A line graph showing percent change over time in treatment response with Estradiol transdermal patches of various sizes (7.75, 15.5, 18.6, and 31 cm²) compared to placebo. The x-axis represents baseline and visits at 6, 12, 18, and 24 months, while the y-axis shows percent change. Each line corresponds to a different patch size or placebo.*

FDA Label Image

Instructions For Use Figure A (Image 07)

Estradiol transdermal system patch packaging label for continuous delivery with once-weekly dosing. The label indicates it contains 1 system and bears the Mylan logo, matching the product by A-S Medication Solutions with NDC 50090-7987.*

FDA Label Image

Instructions For Use Figures B And C (Image 08)

Illustrations showing the removal process of an estradiol transdermal patch. Images highlight tear notches on the patch packaging for easy opening, depict peeling back the packaging to access the patch, and demonstrate careful removal of the estradiol patch from its backing.*

FDA Label Image

Instructions For Use Figures D And E (Image 09)

An instructional illustration showing the Estradiol transdermal patch and its protective liner. Figure D is a close-up of the patch with the protective liner labeled. Figure E shows hands peeling the protective liner off the circular patch before application.*

FDA Label Image

Instructions For Use Figures F And G (Image 10)

An instructional illustration showing the application of an Estradiol transdermal patch. Figure F depicts a person applying the circular patch to the abdomen area, while Figure G shows application to the buttocks. The images indicate appropriate placement sites for the patch on the body.*

FDA Label Image

Instructions For Use Figure H (Image 11)

Illustration showing a hand holding a transdermal patch of Estradiol, labeled with strength .0375 mg/d and the labeler A-S Medication Solutions. The patch appears round and is positioned on the skin, demonstrating the proper placement for use.*

FDA Label Image

Label Image (Lbl500907987)

The image shows packaging for Estradiol transdermal patch, 0.0375 mg/day, labeled for once-weekly use by A-S Medication Solutions. The label includes product NDC 50090-7987-0, storage instructions to keep at 68 to 77 degrees Fahrenheit and not to store unopened patches beyond the expiration date. The package contains 4 transdermal systems.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.